Recent developments in the management of IgA nephropathy, a rare kidney disorder characterized by the deposition of IgA antibodies in the glomeruli, have sparked interest in targeted therapies that aim to reduce proteinuria and improve renal function. The APPLAUSE-IgAN study has provided promising interim results regarding iptacopan (Fabhalta), an investigational drug acting on the alternative complement pathway. This article delves into the interim findings reported at the 2024 American Society of Nephrology Kidney Week meeting, shedding light on their clinical significance, potential implications for kidney health, and remaining questions regarding the long-term benefits of iptacopan.
In a phase III clinical trial involving 250 patients diagnosed with IgA nephropathy, iptacopan demonstrated a statistically significant reduction in proteinuria. Specifically, the adjusted geometric mean 24-hour urinary protein-to-creatinine ratio (UPCR) was reduced by 38.3% (P
Leave a Reply